Serum polysialylated neural cell adhesion molecule in childhood neuroblastoma
1998

Serum Polysialylated NCAM in Childhood Neuroblastoma

Sample size: 14 publication Evidence: moderate

Author Information

Author(s): S Gluerl, C Schelp, N Madry, D von Schweinitzl, M Eckhardt, R Gerardy-Schahn

Primary Institution: Medical School Hannover

Hypothesis

Serum polysialylated NCAM levels can serve as a prognostic marker for childhood neuroblastoma.

Conclusion

Serum levels of polysialylated NCAM are significantly elevated in children with advanced neuroblastoma and decrease during successful therapy.

Supporting Evidence

  • Serum levels of polysialylated NCAM were more than sixfold higher in children with advanced neuroblastoma.
  • Serum concentrations correlated with the polysialylated NCAM content of the tumours.
  • Serum levels decreased during successful therapy.

Takeaway

This study found that a special protein in the blood can help doctors see how serious a child's neuroblastoma is and if treatment is working.

Methodology

Serum levels of polysialylated NCAM were measured in 14 children with neuroblastoma and compared to 269 healthy controls using an immunoluminescence assay.

Limitations

The study had a small sample size and did not establish an age-dependent decrease in serum polysialylated NCAM.

Participant Demographics

14 children with neuroblastoma and 269 healthy control subjects aged 1 day to 16 years.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication